Publication details

The immunogenicity of p24 protein from HIV-1 virus is strongly supported and modulated by coupling with liposomes and mannan

Authors

ZACHOVA K. BARTHELDYOVA E. HUBATKA F. KRUPKA M. ODEHNALOVA N. TURANEK KNOTIGOVA P. VAŠKOVICOVÁ Naděžda SLOUPENSKA K. HROMADKA R. PAULOVICOVA E. EFFENBERG R. LEDVINAE M. RASKA M. TURANEKA J.

Year of publication 2024
Type Article in Periodical
Magazine / Source Carbohydrate Polymers
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.sciencedirect.com/science/article/pii/S0144861724000705?via%3Dihub
Doi http://dx.doi.org/10.1016/j.carbpol.2024.121844
Keywords Liposomes; Mannan; Recombinant protein; Adjuvants; Bioconjugation; Oxime ligation
Description Anti-viral and anti-tumor vaccines aim to induce cytotoxic CD8+ T cells (CTL) and antibodies. Conserved protein antigens, such as p24 from human immunodeficiency virus, represent promising component for elicitation CTLs, nevertheless with suboptimal immunogenicity, if formulated as recombinant protein. To enhance immunogenicity and CTL response, recombinant proteins may be targeted to dendritic cells (DC) for cross presentation on MHCI, where mannose receptor and/or other lectin receptors could play an important role. Here, we constructed liposomal carrier-based vaccine composed of recombinant p24 antigen bound by metallochelating linkage onto surface of nanoliposomes with surface mannans coupled by aminooxy ligation. Generated mannosylated proteonanoliposomes were analyzed by dynamic light scattering, isothermal titration, and electron microscopy. Using murine DC line MutuDC and murine bone marrow derived DC (BMDC) we evaluated their immunogenicity and immunomodulatory activity. We show that p24 mannosylated proteonanoliposomes activate DC for enhanced MHCI, MHCII and CD40, CD80, and CD86 surface expression both on MutuDC and BMDC. p24 mannosylated liposomes were internalized by MutuDC with p24 intracellular localization within 1 to 3 h. The combination of metallochelating and aminooxy ligation could be used simultaneously to generate nanoliposomal adjuvanted recombinant protein-based vaccines versatile for combination of recombinant antigens relevant for antibody and CTL elicitation.

You are running an old browser version. We recommend updating your browser to its latest version.

More info